Phase Advance technology is the sieve that separates the 3% winners from the haystack of losers in a portfolio at discovery phase & rank them for drug developers by extent of success including predicting the “good” black swan event of blockbusters.
Phase Advance is an engine that enables CROs to design successful clinical trials before they undertake them, thereby optimizing clinical trial design to make them smaller, faster, and more likely to lead to licensing.
We design successful clinical trials by generating:
Phase Advance is the engine that helps investors only invest in molecules with >99% chance of succeeding in phase 3, before first-in-human studies, increasing the ROI for R&D from 1.2-6.8% to more than 90% & by changing the Net Present Value for molecules selected to go into drug development.
De-risk investment from assets unlikely to work
Phase Advance partners with AI drug discovery companies to carry their discoveries forward to the next stage: preclinical translational work to establish potential efficacy, PK/PD, and long-term outcomes for target diseases.
Prioritize leads with highest success rate
Identify leads that will outperform competition
Lead optimization insights and improved parameters or combo therapeutics
